Listed by the USPTO as SIFFORD, JEFFREY MARK
Tech Center 1600 • Art Units: 1648 1653 1671
This examiner grants 55% of resolved cases
SIFFORD, JEFFREY MARK is assigned to tech center 1600 and art unit 1648. The record contains 89 resolved cases, an allowance rate of 55.1%, and a median of 1223 days to allowance. The 32.8% interview lift is prominent relative to the allowance rate as a percentage measure. The 1223-day median indicates that matters may require extended prosecution even when they ultimately reach allowance.
The companies most represented are Intervet Inc., Takeda Pharmaceutical Company Limited, and Sartorius Bia Separations D O O. The firms are Christensen, Fonder, Dardi & Busse PLLC, OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and Riverside Law LLP. The limited resolved-case total makes the profile directional, but its company and firm list can help identify relevant experience in art unit 1648.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18569776 | CORONAVIRUS GLYCOSYLATION VARIANT VACCINES | Non-Final OA | ModernaTX, Inc. |
| 17911367 | KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME | Final Rejection | Wisconsin Alumni Research Foundation |
| 18569144 | DEVELOPMENT AND VALIDATION OF A 2-GENE HOST-VIRAL TRANSCRIPTOMIC CLASSIFIER FOR ENHANCED COVID-19 DIAGNOSIS | Non-Final OA | The Regents of the University of California |
| 18022056 | ADENO-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED EXPRESSION LEVELS | Non-Final OA | California Institute of Technology |
| 17412900 | Stable Reporter Flavivirus | Non-Final OA | Board of Regents, the University of Texas System |
| 17615961 | MDBK IRF3/IRF7 KNOCK OUT MUTANT CELL AND ITS USE FOR VACCINE PRODUCTION | Non-Final OA | Intervet Inc. |
| 17919997 | COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES | Final Rejection | DUKE UNIVERSITY |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | Final Rejection | TAKEDA VACCINES, INC. |
| 17274016 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | Non-Final OA | Takeda Vaccines, Inc. |
| 18000638 | CHIMERIC ADENOVIRAL VECTORS | Non-Final OA | Vaxart, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.1% of resolved applications examined by Jeffrey Mark Sifford were allowed (89 resolved cases), compared with 49.6% across Art Unit 1648 over the last five years.
This examiner's interview lift is +32.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jeffrey Mark Sifford took 1,223 days on average from filing to allowance.
Jeffrey Mark Sifford examines applications in Art Unit 1648 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
